Department of Nephrology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
World J Pediatr. 2018 Apr;14(2):121-126. doi: 10.1007/s12519-018-0125-y. Epub 2018 Mar 12.
Calcineurin inhibitors (CNIs) are commonly given to transplant recipients of kidneys and other solid organs and to patients with immune disorders, such as steroid-resistant nephrotic syndrome, steroid-dependent nephrotic syndrome, and frequent relapse nephrotic syndrome. Although CNIs remain the most effective available immunosuppressant agent, there is clinical concern regarding possible long-term nephrotoxicity. This concern is especially significant in children who have a longer life expectancy and greater growth rate.
In this review, we analyzed the literatures to identify original articles that examined use of CNIs in children who received organ transplantation and nephropathy to assess the available evidence of their nephrotoxicity. PubMed, Elsevier, and Tompson ISI Web of Knowledge were searched for identifying relevant papers.
Clinical research supports the presence of CNI-related nephrotoxicity. However, some researchers have questioned the prevalence and seriousness of chronic CNIs nephrotoxicity, especially because the pathological lesions typically associated with long-term CNI use are nonspecific. Many researchers have focused on early markers of CNI nephrotoxicity, and the methods that may help prevent and manage nephrotoxicity.
Future research should focus on investigating early markers of CNI nephrotoxicity and strategies for improved immunosuppressant therapy, and developing alternative treatments. CNI-mediated nephrotoxicity should always be taken seriously in clinic.
钙调磷酸酶抑制剂(CNI)常用于肾和其他实体器官移植受者以及免疫性疾病患者,如激素耐药性肾病综合征、激素依赖性肾病综合征和频繁复发的肾病综合征。虽然 CNI 仍然是最有效的免疫抑制剂,但人们对其可能的长期肾毒性存在临床担忧。对于预期寿命更长和生长速度更快的儿童来说,这种担忧尤其重要。
在这篇综述中,我们分析了文献,以确定检查 CNI 在接受器官移植和肾病的儿童中使用的原始文章,以评估其肾毒性的现有证据。我们在 PubMed、Elsevier 和汤姆森 ISI Web of Knowledge 上搜索了相关论文。
临床研究支持 CNI 相关肾毒性的存在。然而,一些研究人员对慢性 CNI 肾毒性的普遍性和严重性提出了质疑,特别是因为与长期 CNI 使用相关的病理损伤通常是非特异性的。许多研究人员专注于 CNI 肾毒性的早期标志物,以及可能有助于预防和管理肾毒性的方法。
未来的研究应集中于调查 CNI 肾毒性的早期标志物和改善免疫抑制剂治疗的策略,并开发替代治疗方法。在临床中,应始终认真对待 CNI 介导的肾毒性。